BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fallahi P, Ferrari SM, Elia G, Ragusa F, Patrizio A, Paparo SR, Marone G, Galdiero MR, Guglielmi G, Foddis R, Cristaudo A, Antonelli A. Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin. Semin Cancer Biol 2020:S1044-579X(20)30149-8. [PMID: 32569821 DOI: 10.1016/j.semcancer.2020.06.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Elia G, Patrizio A, Ragusa F, Paparo SR, Mazzi V, Balestri E, Botrini C, Rugani L, Benvenga S, Materazzi G, Spinelli C, Antonelli A, Fallahi P, Ferrari SM. Molecular features of aggressive thyroid cancer. Front Oncol 2022;12:1099280. [PMID: 36605433 DOI: 10.3389/fonc.2022.1099280] [Reference Citation Analysis]
2 Li G, Chen W, Gong Y, Wei T, Gong R, Zhu J, Li Z, Lei J. Identification of Circulating Exosomal microRNAs Associated with Radioiodine Refractory in Papillary Thyroid Carcinoma. J Pers Med 2022;12. [PMID: 36556238 DOI: 10.3390/jpm12122017] [Reference Citation Analysis]
3 Zeng L, Yuan S, Zhou P, Gong J, Kong X, Wu M. Circular RNA Pvt1 oncogene (CircPVT1) promotes the progression of papillary thyroid carcinoma by activating the Wnt/β-catenin signaling pathway and modulating the ratio of microRNA-195 (miR-195) to vascular endothelial growth factor A (VEGFA) expression. Bioengineered 2021;12:11795-810. [PMID: 34927541 DOI: 10.1080/21655979.2021.2008639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
4 Li LR, Du B, Liu HQ, Chen C. Artificial Intelligence for Personalized Medicine in Thyroid Cancer: Current Status and Future Perspectives. Front Oncol 2020;10:604051. [PMID: 33634025 DOI: 10.3389/fonc.2020.604051] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]